These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38721284)

  • 1. Chemoablation with UGN-102 in intermediate-risk non-muscle invasive bladder cancer, are we there yet?
    González-Padilla DA; Subiela JD; Villacampa-Aubá F
    Transl Androl Urol; 2024 Apr; 13(4):639-642. PubMed ID: 38721284
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
    Prasad SM; Huang WC; Shore ND; Hu B; Bjurlin M; Brown G; Genov P; Shishkov D; Khuskivadze A; Ganev T; Marchev D; Orlov I; Kopyltsov E; Zubarev V; Nosov A; Komlev D; Burger B; Raju S; Meads A; Schoenberg M
    J Urol; 2023 Oct; 210(4):619-629. PubMed ID: 37548555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.
    Chevli KK; Shore ND; Trainer A; Smith AB; Saltzstein D; Ehrlich Y; Raman JD; Friedman B; D'Anna R; Morris D; Hu B; Tyson M; Sankin A; Kates M; Linehan J; Scherr D; Kester S; Verni M; Chamie K; Karsh L; Cinman A; Meads A; Lahiri S; Malinowski M; Gabai N; Raju S; Schoenberg M; Seltzer E; Huang WC
    J Urol; 2022 Jan; 207(1):61-69. PubMed ID: 34433303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes.
    Linehan J; Gottlieb J; Woldu SL; Labbate C; Rose K; Sexton W; Kaimakliotis H; Jacob J; Dickstein R; Nieder A; Bjurlin M; Humphreys M; Ghodoussipor S; Quek M; O'Donnell M; Eisner BH; Feldman AS; Matin SF; Lotan Y; Murray KS
    Eur Urol Focus; 2023 Nov; 9(6):1052-1058. PubMed ID: 37263827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.
    Labbate C; Woldu S; Murray K; Rose K; Sexton W; Tachibana I; Kaimakliotis H; Jacob J; Dickstein R; Linehan J; Nieder A; Bjurlin M; Humphreys M; Ghodoussipour S; Quek M; O'Donnell M; Eisner B; Feldman A; Lotan Y; Matin SF
    J Urol; 2023 May; 209(5):872-881. PubMed ID: 36657029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial.
    Kleinmann N; Matin SF; Pierorazio PM; Gore JL; Shabsigh A; Hu B; Chamie K; Godoy G; Hubosky S; Rivera M; O'Donnell M; Quek M; Raman JD; Knoedler JJ; Scherr D; Stern J; Weight C; Weizer A; Woods M; Kaimakliotis H; Smith AB; Linehan J; Coleman J; Humphreys MR; Pak R; Lifshitz D; Verni M; Adibi M; Amin MB; Seltzer E; Klein I; Konorty M; Strauss-Ayali D; Hakim G; Schoenberg M; Lerner SP
    Lancet Oncol; 2020 Jun; 21(6):776-785. PubMed ID: 32631491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Systematic Review and Meta-analysis of Chemoablation for Non-muscle-invasive Bladder Cancer.
    Yanagisawa T; Quhal F; Kawada T; Mostafaei H; Motlagh RS; Laukhtina E; Rajwa P; Deimling MV; Bianchi A; Pallauf M; Majdoub M; Pradere B; Moschini M; Karakiewicz PI; Teoh JY; Miki J; Kimura T; Shariat SF
    Eur Urol Focus; 2023 May; 9(3):463-479. PubMed ID: 36517409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors.
    Jacob JM; Woldu SL; Linehan J; Labbate C; Rose KM; Sexton WJ; Tachibana I; Kaimakliotis H; Nieder A; Bjurlin MA; Humphreys M; Ghodoussipour SB; Quek ML; Johnson B; O'Donnell M; Eisner BH; Feldman AS; Murray KS; Matin SF; Lotan Y; Dickstein RJ
    Urol Oncol; 2024 Jan; 42(1):20.e17-20.e23. PubMed ID: 37517898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
    Woldu SL; Labbate C; Murray KS; Rose K; Sexton W; Tachibana I; Kaimakliotis H; Jacob J; Dickstein R; Linehan J; Nieder A; Bjurlin MA; Humphreys M; Ghodoussipour S; Quek ML; O'Donnell M; Eisner BH; Feldman AS; Matin SF; Lotan Y
    Urol Oncol; 2023 Mar; 41(3):147.e15-147.e21. PubMed ID: 36424224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comment on "Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report".
    Song Y; Du Y; Qin C; Xu T
    World J Urol; 2022 May; 40(5):1251-1252. PubMed ID: 35191990
    [No Abstract]   [Full Text] [Related]  

  • 11. Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report.
    Matin SF; Pierorazio PM; Kleinmann N; Gore JL; Shabsigh A; Hu B; Chamie K; Godoy G; Hubosky SG; Rivera M; O'Donnell M; Quek M; Raman JD; Knoedler JJ; Scherr D; Weight C; Weizer A; Woods M; Kaimakliotis H; Smith AB; Linehan J; Coleman J; Humphreys MR; Pak R; Lifshitz D; Verni M; Klein I; Konorty M; Strauss-Ayali D; Hakim G; Seltzer E; Schoenberg M; Lerner SP
    J Urol; 2022 Apr; 207(4):779-788. PubMed ID: 34915741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma.
    Kaimakliotis HZ; Tachibana I; Woldu S; Labbate C; Jacob J; Murray K; Rose K; Sexton W; Dickstein R; Linehan J; Nieder A; Bjurlin M; Humphreys M; Ghodoussipour S; Quek M; O'Donnell M; Eisner BH; Matin SF; Lotan Y; Feldman AS
    Urol Oncol; 2023 Sep; 41(9):387.e1-387.e7. PubMed ID: 37246135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer.
    Mostafid AH; Porta N; Cresswell J; Griffiths TRL; Kelly JD; Penegar SR; Davenport K; McGrath JS; Campain N; Cooke P; Masood S; Knowles MA; Feber A; Knight A; Catto JWF; Lewis R; Hall E
    BJU Int; 2020 Jun; 125(6):817-826. PubMed ID: 32124514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: Primary Chemoablation of Low-grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-containing Reverse Thermal Gel (OLYMPUS): An Open-label, Single-arm, Phase 3 Trial.
    Ourfali S; Colombel M
    Eur Urol; 2021 Jan; 79(1):162. PubMed ID: 32891427
    [No Abstract]   [Full Text] [Related]  

  • 15. Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease.
    Rose KM; Murray KS; Labbate C; Woldu S; Linehan J; Jacob J; Kaimakliotis H; Dickstein R; Feldman A; Matin SF; Lotan Y; Humphreys MR; Sexton WJ
    Eur Urol Focus; 2023 Sep; 9(5):807-812. PubMed ID: 37059620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antegrade Instillation of UGN-101 (Mitomycin for Pyelocalyceal Solution) for Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience.
    Rosen GH; Nallani A; Muzzey C; Murray KS
    J Urol; 2022 Jun; 207(6):1302-1311. PubMed ID: 35130080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in chemoablation in upper tract urothelial carcinoma: overview of indications and treatment patterns.
    Gottlieb J; Linehan J; Murray KS
    Transl Androl Urol; 2023 Sep; 12(9):1449-1455. PubMed ID: 37814691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoablation in Urothelial Carcinoma: A Systematic Review and Future Perspectives.
    Alsyouf M; Pierorazio P; Groegler J; Hu B
    Urology; 2020 Oct; 144():28-37. PubMed ID: 32540302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ablative therapy with UGN-102 for low-grade intermediate risk non-muscle-invasive bladder cancer: ready for primetime?
    Lichtbroun B; Ghodoussipour S; Packiam VT
    Transl Androl Urol; 2024 Apr; 13(4):647-649. PubMed ID: 38721287
    [No Abstract]   [Full Text] [Related]  

  • 20. Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-muscle-invasive Bladder Cancer.
    Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi P
    Eur Urol Oncol; 2019 Sep; 2(5):576-583. PubMed ID: 31411974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.